NeuroLume: A Novel Framework Towards Multimodal Detection of Alzheimer's Disease Using EEG and Speech Biomarkers With Explainable Machine Learning
ISEF · 2026 Translational Medical Science
Overview
Alzheimer's disease (AD) is a progressive neurodegenerative disease that continues to be difficult to diagnose in early stages. Despite studies demonstrating that when caught early, cognitive decline can be slowed by over 25%, timely diagnostic access remains limited as current clinical methods are costly and invasive. Furthermore, despite high accuracies from current models, clinical adoption remains slow as opaque models limit clinical interpretability. Thus, we present Neurolume: the first interpretable, low-cost, and non-invasive multimodal machine learning framework for early-stage Alzheimer's disease detection using EEG and speech biomarkers. EEG and speech data was first processed then analysed using interpretable and deep-learning models, including SVMs, CNNs, and a Transformer. Calibrated outputs from each modality were combined using late-stage fusion to estimate Alzheimer's disease probability. The EEG SVM provided stable feature-level interpretability while the CNN detected local spatiotemporal brain patterns producing AUC ˜ 0.91. The speech CNN failed to generalize, but the Transformer model captured linguistic and semantic cues of cognitive decline effectively, achieving high accuracy and AUC ˜ 0.95. Combining calibrated outputs from both modalities produced a robust multimodal classifier with AUC = 0.991, significantly surpassing all single-modality models and enabling reliable, non-invasive Alzheimer's detection. These results demonstrate that integrating interpretable neural and linguistic biomarkers enables accurate, scalable, and non-invasive early detection of Alzheimer's disease, with massive potential applications in improving accessibility to early screening.
Competition history
- ISEF 2026
Resources
Related projects
ISEF · 2025
A Novel Multi-Modal Deep Learning Approach With Attention Mechanisms for Early Detection of Alzheimer's Disease
ISEF · 2026
XAI-Driven Biomarker Discovery for Early Alzheimer's Detection
ISEF · 2025
NeuroSyncNN: A Novel Multimodal Neurodegenerative Disease Diagnostics Framework Leveraging Computer Vision, Image Processing and IoMT Targeting Efficient, Real-Time Automated Brain Mapping and Neural-Signal Decoding
ISEF · 2026
Multimodal Prediction of Alzheimer's Disease: An AI-Ensembled Approach Integrating MRI Imaging and Blood Based Biomarkers
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair